Up 32 cents in this market aint too shabby.
Sit back and enjoy the ride. This company is still lightly followed and good news should continue to come their way.
Ya still think 2020?
FOLD has come a long way from 2 dollar range so lots of profit to be booked.
Like they always say...MARK THIS POST. FOLD will be 15 by the end of June as I have faith in management. News flow will be heavy very soon.
Yup. I get your point and respect the fact that you expect a company to be run efficiently. I'm all for that and thank the stars above that at least 99% of listed companies are run far better than our government branches!
No need to apologize for your opinion and yes I would like the submissions in yesterday but as someone who has followed biotech for almost 30 years now, I feel that FOLD has done a very good job in getting Migalistat to where it is now.
Look at it this way. If you are still bullish then this little down time gives you a chance to accumulate. Also remember that the bios have pulled back quite a bit and maybe, just maybe, news is better released when they are more in favor.
Ron-When you speak of submissions, do you mean the drug applications? Remember FOLD is actually ahead of schedule from where they though they would be just a few months ago.
For over a week, I have not been able to post on Yahoo but have been reading and staying updated.
First let me say that the conference call was superb. Mr. Crowley and the rest of his team will soon have a financial juggernaut on their hands, this unless a smart suitor takes them out. There is no immediate need for financing and that along with Migalistat showing great promise makes Amicus quite undervalued.
Below is something from this weekend's Barrons. I picked out these two paragraphs because they describe exactly what Mr. Crowley pitched to the FDA that got the ball rolling on FOLD's therapy, a specific biomarker that helps treat victims of Fabrey's disease. I am more bullish on FOLD now more than ever and added to my position on Thursday. I think the 10.95 I paid for it will look like bargain basement by summer.
Please don't make me explain the insider transaction deal to you other than to say this...They sell for many reasons but buy for just one.
In a nutshell, his sale is meaningless.
Not sure what to think about the data as from my layman's point of view, it looks just ok and probably won't cause huge moves one way or the other.
My only thought is that as someone who has been reading biotech press releases for 30 years, the writing of this one did seem to be a bit "hyped". I will watch today's action and decide what to do from here.
First of all, real nice analysis and I agree that 20% premium is cheap for FOLD. After all you get a close to market drug that helps to prove the value of the entire companies platform.
That being said, I am pretty confident in saying that Mr. Crowley won't let this company go for a song and a dance. My guess is that if he can't get 2 billion then he will just keep building FOLD into a bigger and bigger player. Either way I'm more than content to just let it play out.